Our novel studies suggest that PEDF-mediated downregulation of pro-metastatic mediators is associated with menopausal status and BC subtype, and likely accounts for the enhanced anti-metastatic action of PEDF observed in TNBC and ER+/HER2- BC cells under different menopausal oestrogen conditions (manuscript submitted). Here, ERBB2 is linked to breast cancer.